Cabzored 80mg

Cabzored is a medication used to treat advanced renal cell carcinoma (RCC) and medullary thyroid cancer (MTC). It is an oral tablet that works by inhibiting the activity of enzymes called tyrosine kinases, which are involved in the growth and spread of cancer cells.

Composition:

Cabzored contains Cabozantinib, a medication that is a tyrosine kinase inhibitor.

Indications:

Cabzored is indicated for the treatment of:

1. Advanced renal cell carcinoma (RCC) in patients who have received prior therapy
2. Medullary thyroid cancer (MTC) in patients who have progressed on prior treatment or have symptomatic or rapidly progressing disease

Mechanism of Action:

Cabozantinib works by:

1. Inhibiting the activity of enzymes called tyrosine kinases, which are involved in the growth and spread of cancer cells
2. Reducing the production of vascular endothelial growth factor (VEGF), a protein that promotes blood vessel formation and tumor growth

Dosage and Administration:

The recommended dosage of Cabzored is:

• 80mg taken orally once daily
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Cabzored include:

1. Fatigue
2. Diarrhea
3. Abdominal pain
4. Nausea and vomiting
5. Headache
6. Dizziness
7. Palpitations

Serious side effects can include:

1. Hypertension (high blood pressure)
2. Hemorrhage
3. Gastrointestinal perforation
4. Hepatotoxicity (liver damage)
5. Pancreatitis

Contraindications:

Cabzored is contraindicated in patients with:

1. Hypersensitivity to Cabozantinib or other tyrosine kinase inhibitors
2. Severe liver disease
3. Severe kidney disease

Precautions:

1. Patients with a history of cardiovascular disease should be closely monitored while receiving Cabzored.
2. Patients with a history of liver disease should be closely monitored while receiving Cabzored.
3. Patients with a history of kidney disease should be closely monitored while receiving Cabzored.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of diarrhea or abdominal pain.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.